NCT05362045View on ClinicalTrials.gov

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

August 19, 2022

Study Completion Date

August 19, 2022

Conditions
Healthy Participants
Interventions
DRUG

Mavacamten

Specified dose on specified days

Trial Locations (4)

33014

Clinical pharmacology of Miami, Miami

33147

Advanced Pharma CR, LLC, Miami

65802

QPS Springfield, Springfield

78744

Ppd Phase I Clinic, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05362045 - A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants | Biotech Hunter | Biotech Hunter